Asked by: Beth Winter (Labour - Cynon Valley)
Question to the Department for Transport:
To ask the Secretary of State for Transport, how many medical professionals' assessments of fitness to drive have been received by the DVLA in each month of the last five years.
Answered by Guy Opperman - Parliamentary Under-Secretary (Department for Transport)
The Driver and Vehicle Licensing Agency (DVLA) is currently engaging with the Professional Fees Committee of the British Medical Association in respect of the fees paid for medical information required for driver licensing purposes.
The DVLA is also reviewing the questionnaires issued to medical professionals when medical information is required to assist in assessing an individual’s fitness to drive; with a view to simplifying the process wherever possible.
The DVLA has introduced a simplified licence renewal process for drivers with epilepsy, multiple sclerosis, some mental health conditions, and glaucoma. This renewal process has significantly reduced the need for the DVLA to seek further information from medical professionals and enabled more licensing decisions to be made based on the information provided by the driver. The DVLA is considering adding more medical conditions to this process.
In July 2022, the law changed to widen the pool of registered healthcare professionals who can provide information as part of the DVLA’s medical investigations into a person’s fitness to drive. Previously, this could only be provided by a doctor. This provides GP surgeries and hospital teams greater flexibility to decide how they manage the DVLA’s requests for information.
These changes will all help to simplify or reduce the number of times the DVLA needs to seek further information from medical professionals.
The length of time taken to process a driving licence application where a medical condition needs to be investigated depends on the condition(s) involved and if further medical information, tests, or examinations are required.
The DVLA, acting on behalf of the Secretary of State for Transport, is required to ensure that all drivers meet the medical standards for driving before a licence is issued. These investigations can often involve seeking further information about an individual’s medical condition(s) from the relevant healthcare professionals. However, it is important to note that the DVLA does not ask medical professionals to assess an individual’s fitness to drive, and as such, figures about how many such assessments have been received from medical professionals are not available.
Asked by: Dean Russell (Conservative - Watford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support exists for those with (a) Huntington’s disease and (b) other complex neurological conditions.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Integrated care boards (ICBs) are responsible for commissioning most services for people with neurological conditions, including those with Huntington’s disease. At a national level, NHS England commissions the specialised elements of neurological care that patients may receive from 27 specialised neurological treatment centres across England. NHS England’s RightCare toolkit and Getting It Right First Time programme aim to improve care for people with neurological conditions, by reducing variation and delivering care more equitably across England.
New optimal clinical pathways for a range of neurological conditions were developed by the National Neurosciences Advisory Group, which ceased operation in 2022. These pathways set out what good treatment, care, and support should look like across a range of neurological conditions. They also help to guide and facilitate the commissioning of high-quality, effective neurology services by ICBs. The optimal clinical pathway for movement disorders outlines the care pathway that patients with Huntington’s disease should receive. Further information on the optimal clinical pathways are available at the following link:
https://www.nnag.org.uk/optimum-clinical-pathways
The Department funds research on neurological conditions through the National Institute for Health and Care Research (NIHR), and between 2018/19 and 2022/23, the Department spent £272.1 million on research into neurological conditions. This covers research into conditions such as Huntington’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. In 2022/23, the most recent year for which we have data, the Department, via the NIHR, spent £65.3 million on research into neurological conditions.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the level of stocks of epilepsy medication in south London pharmacies as of 12 April 2024.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has a role to play in ensuring that supplies of medicines are available nationally, and in sufficient quantity to meet demand. The Department does not monitor stocks of medicine at a local level, and as such no assessment has been made of the level of stocks of epilepsy medication in South London pharmacies.
The Department has been working intensively with the pharmaceutical industry, National Health Service, and others to address issues with the supply of some epilepsy medications. As a result of our action, some supply issues with Tegretol prolonged-release tablets have been resolved. However, some issues remain, and we are working with suppliers to resolve these as soon as possible by expediting future deliveries, and ensuring that alternative products remain available. We have issued guidance to healthcare professionals on how to manage patients requiring affected medicines while supply is disrupted. The Department has been engaging with the Epilepsy Society to keep them updated on developments.
Asked by: Helen Hayes (Labour - Dulwich and West Norwood)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she is taking steps to increase supplies of epilepsy medication in south London.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has a role to play in ensuring that supplies of medicines are available nationally, and in sufficient quantity to meet demand. The Department does not monitor stocks of medicine at a local level, and as such no assessment has been made of the level of stocks of epilepsy medication in South London pharmacies.
The Department has been working intensively with the pharmaceutical industry, National Health Service, and others to address issues with the supply of some epilepsy medications. As a result of our action, some supply issues with Tegretol prolonged-release tablets have been resolved. However, some issues remain, and we are working with suppliers to resolve these as soon as possible by expediting future deliveries, and ensuring that alternative products remain available. We have issued guidance to healthcare professionals on how to manage patients requiring affected medicines while supply is disrupted. The Department has been engaging with the Epilepsy Society to keep them updated on developments.
Asked by: Lisa Nandy (Labour - Wigan)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure adequate levels of supply of medications prescribed for epilepsy.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
There are around 14,000 medicines licensed for supply in the United Kingdom, and while most are in good supply, there can sometimes be supply issues with a limited number of medicines. The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the UK, as well as the other countries around the world.
The Department has been working intensively to address issues with the supply of some epilepsy medications. Guidance has been issued to healthcare professionals on how to manage patients requiring affected medicines while supply is disrupted.
We will continue to work closely with industry, the National Health Service, and others to help ensure patients continue to have access to an alternative treatment until their usual product is back in stock. The Department has been engaging with the Epilepsy Society, and we will continue to keep them updated on any developments.
Asked by: Kevin Brennan (Labour - Cardiff West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department plans to take in the next year to help ensure that children with severe epilepsy can access effective cannabis-based medications through the NHS.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The licensed cannabis-based medicine epidyolex is prescribed routinely for three forms of epilepsy, for patients aged two years old and above. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.
We continue to call on the manufacturers of these products to conduct research, and we are working with regulatory, research, and National Health Service partners to establish clinical trials to test the safety and efficacy of these products, to enable evidence based prescribing decisions.
Asked by: Peter Grant (Scottish National Party - Glenrothes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that there is an adequate supply of oxcarbazepine for patients with epilepsy.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department was informed of supply issues with oxcarbazepine 150 milligram and 300 milligram tablets by one supplier, which are out of stock until the end of March and the end of February 2024, respectively. Alternative oxcarbazepine tablets remain available. The Department has worked extensively with alternative suppliers and clinical colleagues and has since issued communications to the National Health Service which includes detailed management advice.
While we cannot always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise and help mitigate risks to patients. There is a team within the Department that deals specifically with medicine supply problems, and it works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, the devolved administrations, and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.
Asked by: Sarah Dyke (Liberal Democrat - Somerton and Frome)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when she expects the randomised controlled trials to test medicinal cannabis for adults and children with epilepsy to begin; which NHS Trusts will be participating in these trials; how many patients will be involved in the trials; and whether patients will be approached to participate.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department, via the National Institute for Health and Care Research, is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and results will be published once the trials have been completed and the findings peer reviewed. The trial details are in development.
Asked by: Sarah Dyke (Liberal Democrat - Somerton and Frome)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.
Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.
Asked by: Catherine West (Labour - Hornsey and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people in prison have epilepsy.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
NHS England collects internal management data on this however the statistics are not considered robust enough to be published.